Technology Investing: One VC's View of the Value Proposition for Today's Market
This article was originally published in Start Up
Executive Summary
Technology-based discovery start-ups step up to the plate with two strikes against them. New pharmaceutical technologies have thus far failed to accelerate discovery or reduce drug development times, and thus failed to solve the industry's R&D productivity dilemma. And in-licensing companies have proliferated, making the value proposition for investing in new discovery-oriented companies tougher to support. Nonetheless, finely tuned rationales for making such investments do exist, premised on the twin rationales of shortcuts through the mire of biological risk and freedom to operate through the minefield of industry patents.
You may also be interested in...
Profiles of Two Iconoclasts
In recent years, most venture capital firms have focused on investing in companies with well-developed product pipelines. In this issue of START-UP, we profile two trendsetters: Fred Cohen, managing director at Texas Pacific Group Ventures; and Christoph Westphal, formerly a partner at Polaris Ventures and now vice chairman and CEO of Sirtris Pharmaceuticals. Both men are physician scientists turned investors, who have tapped into their scientific and clinical knowledge to make investments in "high concept" discovery stage companies. And although the investments are intriguing, it's too early to say whether or not the strategies adopted by these two men will yield returns for their backers.
Profiles of Two Iconoclasts
In recent years, most venture capital firms have focused on investing in companies with well-developed product pipelines. In this issue of START-UP, we profile two trendsetters: Fred Cohen, managing director at Texas Pacific Group Ventures; and Christoph Westphal, formerly a partner at Polaris Ventures and now vice chairman and CEO of Sirtris Pharmaceuticals. Both men are physician scientists turned investors, who have tapped into their scientific and clinical knowledge to make investments in "high concept" discovery stage companies. And although the investments are intriguing, it's too early to say whether or not the strategies adopted by these two men will yield returns for their backers.
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?
The Vioxx withdrawal is one of those seminal events that, because of the players involved--the industry's largest companies, some of their most valuable drugs, both the European and American regulatory structures--holds up a mirror to an entire industry. Given the record breaking valuation slides, the market is taking a very critical look at the industry's strategies; so should the people who run it.